Top Markets
#1 Islamic Coin Islamic Coin +151.48%
#2 DOVU DOVU +48.44%
#3 Black Phoenix Black Phoenix +34.78%
#4 Velvet Velvet +31.18%
#5 Cross Cross +22.50%
#6 Akedo Akedo +15.95%
#7 DoubleZero DoubleZero +14.89%
#8 Not in Employment, Education, or Training Not in Employment, Education, or Training +11.53%
#9 Fake World Assets Fake World Assets +10.34%
#10 Cap Cap +10.26%
Coin of the day
Islamic Coin Islamic Coin
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Galera Therapeutics, Inc. Galera Therapeutics, Inc.

Galera Therapeutics, Inc.

GRTX
Classement en actions #33957
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
Prix de l'action
$17.15
Dernière synchronisation: 2026-08-03
Capitalisation boursière
$6.51M
Changement (1 jour)
9.80%
Changement (1 an)
289.77%
Pays
US
Échange Galera Therapeutics, Inc. (GRTX)

Catégorie

Healthcare
Bénéfices pour Galera Therapeutics, Inc. (GRTX)
Bénéfices en Mar 2026 TTM : $149.04M
Selon les derniers rapports financiers de Galera Therapeutics, Inc., les bénéfices actuels de l'entreprise sont de $149.04M. En 2023, l'entreprise a réalisé un bénéfice de $-59.08M, une augmentation par rapport à celui de 2022 qui était de $-62.29M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Galera Therapeutics, Inc. de 2017 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
2026 (TTM) $149.04M -877.84%
2024 $-19.16M -67.57%
2023 $-59.08M -5.15%
2022 $-62.29M -22.65%
2021 $-80.53M 8.49%
2020 $-74.23M 42.93%
2019 $-51.94M 117.33%
2018 $-23.90M -0.03%
2017 $-23.91M 0.00%
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B 3,439.37%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B 1,208.85%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B 1,916.79%
BE